The members of the committee unanimously voted in favor of this on Tuesday after hours of discussion. The result of the vote is not binding for the FDA, but the authority usually follows the assessment of the consultants. The CDC has yet to agree. An emergency approval for the preparation could then take place in the coming days.
The vaccine, of which two doses are required, has been available in Germany since the end of February. It’s based on a more classical process than BioNTech/Pfizer’s and Moderna’s mRNA vaccines, so it’s seen as a possible alternative for people who are skeptical about it.
Here’s how Novavax shares are reacting
Papers from Novavax are in high demand on Wednesday following a positive vote by FDA advisers. The shares of the vaccine manufacturer jump at times on the NADSAQ by 7.95 percent to 51.29 euros. They ended up above the 50-day moving average for the first time since the end of 2021, after almost hitting a two-year low again on Friday.
/cah/DP/he
WASHINGTON (dpa-AFX)
Leverage must be between 2 and 20
No data
More news about BioNTech (ADRs)
Image sources: Ascannio / Shutterstock.com